A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

NCT06190301

Primary Ocular Adnexal MALT Lymphoma

RECRUITING NA

Study of Lymphoma in Asia

NCT01584141

Lymphoma, Follicular Lymphoma, Non-Hodgkin Multiple Myleoma +3 more

COMPLETED

A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

NCT06497452

B-cell Non-Hodgkin Lymphoma

RECRUITING

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185

Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma B-cell Non Hodgkin Lymphoma +1 more

COMPLETED

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

NCT05444322

Mantle Cell Lymphoma Diffuse Large B-cell Lymphoma Follicular Lymphoma

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Lymphoma Clinical Trial COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention needed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available.